Conference Reports for NATAP

Back

HepDART 2011 December 4, 2011 - December 8, 2011 Kauai, HI USA     Triple Therapy Using Telaprevir In The Treatment of Hepatitis C Recurrence After Liver Transplantation: An Early Single Center Experience. - (02/03/12)   REAL-LIFE SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC) (12/08/11)   Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (poster presentation) (12/08/11)   Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (oral presentation) (12/08/11)   Biotron study of lead Hepatitis C drug shows virus undetectable in patients after three months: 'First-in-class, new mode of action drug, Novel p7 inhibitor with the potential to increase the potency of current anti-HCV therapy' - 'BIT225 is a novel antiviral compound that inhibits the viroporin function of HIV-1 Vpu and HCV p7.....and a potentially useful agent to target cellular viral reservoirs' (12/08/11)   Characterization of Virologic Resistance in HCV Genotype 1 Null Responders Receiving a Dual Direct- Acting Antiviral Combination of NS3 Protease Inhibitor Asunaprevir (ASV; BMS-650032) and NS5A Replication Complex Inhibitor Daclatasvir (DCV; BMS-790052) (poster presentation) (12/08/11)   Antiviral activity and tolerability of BIT225 plus pegylated interferon alfa-2b and weight-based ribavirin for 28 days in HCV treatment-naïve, genotype 1, mono-infected patients (12/08/11)   Host targeting antiviral (HTA) alisporivir presents a high barrier to resistance both in vitro and in HCV patients with no cross-resistance to DAAs (12/07/11)   Alisporivir Plus Peg-IFN_-2a/Ribavirin Treatment for Chronic Hepatitis C Genotype 1 Treatment-Naïve Patients Shows Superior Sustained Virologic Response Irrespective of IL28B Genotype and High Barrier to Resistance (12/07/11)   Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin (12/07/11)   Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and the Calcineurin Inhibitors Cyclosporine and Tacrolimus (12/07/11)   Coadministration of the HCV Protease Inhibitor Boceprevir Has No Clinically Meaningful Effect on the Pharmacokinetics of the Selective Serotonin Reuptake Inhibitor Escitalopram in Healthy Volunteers (12/07/11)   Treatment Week 12/24 Stopping Rules for Boceprevir (BOC) Combination Therapy with Peginterferon+Ribavirin (PR):Exploratory Analyses of SPRINT-2 and RESPOND-2 (12/07/11)   Sustained Virologic Response in Prior Null Responders to Peginterferon/Ribavirin (PR) After Retreatment With Boceprevir + PR: The PROVIDE Study (12/07/11)   Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients: '75% (30/40) of GT-1, and 38% (9/24) of GT-3 HCV-infected patients achieved plasma HCV RNA below the limit of quantitation with a 7 day monotherapy course of MK-5172' (12/07/11)   Safety and Antiviral Activity of MK-5172, a Next Generation HCV NS3/4A Protease Inhibitor with a Broad HCV Genotypic Activity Spectrum and Potent Activity Against Known Resistance Mutants, in genotype-1 and -3 HCV-Infected Patients (12/07/11)   Population and Clonal Analysis of Resistance-Associated Amino Acid Variants (RAVs) in Viruses From Patients Enrolled in a Phase 2b Study of MK-7009 (Vaniprevir): 'HCV Protease Resistance Persists-Clonal Sequencing-novel double/triple mutations detected up to 300 days after stopping HCV therapy' (12/07/11)   MK-5172, a Second Generation HCV NS3/4A Protease Inhibitor is Active Against Common Resistance Associated Variants (RAVs) and Exhibits Cross-Genotype Activity (12/06/11)   Quantification of the Effect of Adherence to Clinical Outcomes in Telaprevir-based Regimens (12/06/11)   No Significant Effect of the HCV Protease Inhibitor Telaprevir on Pharmacokinetics and Pharmacodynamics of Buprenorphine in HCV-negative Volunteers (12/06/11)   Drug Interaction Profile of Telaprevir (12/06/11)   Futility Rules in Telaprevir Combination Treatment (12/06/11)   Review Activity/Safety: Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV (12/06/11)   PSI-7977 400 mg with PEG/RBV Provides 93% SVR Across HCV GT 1, 2 and 3 (12/05/11)   PSI-7977 with PEG/RBV Elicits Rapid Declines in HCV RNA in Patients with HCV GT-4 and GT-6 (12/05/11)   HepDART: PSI-7977 400 mg with PEG/RBV Provides 93% SVR Across HCV GT 1, 2 and 3 - (12/05/11)   HepDart: Global HCV - (12/01/11)   HepDart: Hepatitis C, A smouldering public-health crisis, 'Silent Epidemic' in U.S. Needs More Funding, Researcher Says - (12/05/11)